Dr Michelle Krishnan, Translational Medicine Leader in Rare Diseases at Roche, will by speaking at our upcoming Festival of Genomics. Her talk Clinical Development in Rare Diseases: Angelman Syndrome, From Disease Biology Insights to Genomic Medicine, will explain how to leverage disease biology insights to drive development of genomic medicines and discuss the cutting-edge clinical trial […]
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
An existing drug used to improve insulin delivery could also be used to treat an aggressive and deadly brain tumour, known as glioblastoma. Glioblastoma (GBM) is a fast-growing tumour that spreads in a web like fashion to infiltrate multiple areas of the brain. As it is not a compact tumour, it is extremely difficult to […]
The early bird rate for our next event D4 (Data-Driven Drug Development) Europe expires this Friday, the only event where attendees will receive data, evidence and case studies from the world’s leading minds in pharma. This meeting is designed specifically to cater for senior people in pharma, combining strategic insights of value to IT/R&D leaders, […]
An Alzheimer’s drug that is used to slow cognitive decline can reverse the brain damage caused by teenage drinking, shows a new rat-based study. Adolescent brains are more susceptible to alcohol damage than adult brains. Excessive teenage drinking reduces the formation of neurons in the hippocampus which impairs learning and memory. The damage can also […]
A reversible chemical technique can separate sperm carrying X chromosomes from sperm carrying Y chromosomes to select the offspring sex of mice. Cells from male mammals contain both an X and Y chromosome. However, sperm cells contain either an X or Y chromosome. As the female egg cell always contains an X chromosome, sperm that […]
A drug that speeds up the regeneration of both mouse and human blood stem cells after radiation exposure could be used to successfully mitigate the side-effects of chemotherapy. Although radiation chemotherapy can be an effective cancer treatment, as it preferentially targets cancer cells over normal body cells, it can cause long lasting side-effects in patients. […]
In any field, data science is an emerging area where roles can be hard to define or quantify by hiring managers. For those looking to employ data scientists within their business, this role can lead to a wealth of unanswered questions. This chapter from our Data Solutions for Drug Development Report, sets out key tips […]
Researchers have revealed the first vaccine purely designed by artificial intelligence (AI). This has the potential to revolutionise the drug discovery process by making it quicker, cheaper and producing more effective drugs. From target discovery to market, the drug discovery process takes on average nine years and millions of dollars. The majority of this time […]
The pharmaceutical industry is capturing an ever-increasing quantity of data, but this is often underutilised by professionals in the perfect place to use this data to their advantage. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or miss […]
Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.
The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by […]
Takeda Pharmaceutical has announced the sizeable first sale in its proposed £10 billion-worth of assets to offset the debt it took on during its acquisition of Shire. The company announced it was divesting eye drug Xiidra to Novartis for $5.3bn total, and its TachoSil Fibrin Sealant Patch to Ethicon for $400 million in case.
Two companies with access to data from the 100,000 Genomes Project have identified patients with previously undiscovered life-threatening kidney and neurological diseases. The companies, Alexion and BioMarin, were part of Genomic England’s Discovery Forum, which grants certain industry research proposals access to data from the project after vetting.
Two separate studies have uncovered insights into why checkpoint-inhibiting immune-oncology (IO) drugs only work for a minority of patients, even when combined with other treatments. The first study uncovered a resistance mechanism within the gut microbiome, while the other relates to cancer cell-produced vesicles.